Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43920176" target="_blank" >RIV/00216208:11120/20:43920176 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/20:N0000100
Result on the web
<a href="https://doi.org/10.1016/j.ahj.2020.04.017" target="_blank" >https://doi.org/10.1016/j.ahj.2020.04.017</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ahj.2020.04.017" target="_blank" >10.1016/j.ahj.2020.04.017</a>
Alternative languages
Result language
angličtina
Original language name
Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study
Original language description
BACKGROUND: Clopidogrel associated with aspirin is the recommended treatment for patients undergoing elective percutaneous coronary intervention (PCI). Although severe PCI-related events are rare, evidence suggests that PCI-related myocardial infarction and myocardial injury are frequent complications that can impact the clinical prognosis of the patients. Antiplatelet therapy with a potent P2Y receptor inhibitor such as ticagrelor may reduce periprocedural ischemic complications while maintaining a similar safety profile as compared with conventional dual antiplatelet therapy by aspirin and clopidogrel in this setting. METHODS: Assessment of Loading with the P2Y inhibitor ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting (ALPHEUS) (NCT02617290) is an international, multicenter, randomized, parallel-group, open-label study in patients with stable coronary artery disease who are planned for an elective PCI. In total, 1,900 patients will be randomized before a planned PCI to a loading dose of ticagrelor 180 mg or a loading dose of clopidogrel (300 or 600 mg) in addition to aspirin. Patients will then receive a dual antiplatelet therapy with aspirin and ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily for 30 days. The primary ischemic end point is PCI-related myocardial infarction (myocardial infarction type 4a or 4b) or major myocardial injury within 48 hours (or at hospital discharge if earlier) after elective PCI/stent. Safety will be evaluated by major bleeding events (Bleeding Academic Research Consortium type 3 or 5) at 48 hours (or discharge if it occurs earlier). CONCLUSION: ALPHEUS is the first properly sized trial comparing ticagrelor to clopidogrel in the setting of elective PCI and is especially designed to show a reduction in periprocedural events, a surrogate end point for mortality.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American Heart Journal
ISSN
0002-8703
e-ISSN
—
Volume of the periodical
225
Issue of the periodical within the volume
July
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
27-37
UT code for WoS article
000541737100005
EID of the result in the Scopus database
2-s2.0-85085342802